Roivant Sciences (NASDAQ:ROIV) CEO Sells $7,022,000.00 in Stock

October 23, 2026 by InsiderTrades.com

Key Points

CEO Eric Venker sold 200,000 Roivant Sciences shares at an average price of $35.11, generating approximately $7.02 million. The sale reduced his ownership by 12.51% and was made under a pre-arranged Rule 10b5-1 trading plan.
Venker has also sold 200,000 shares in each of the prior three months, with those transactions totaling about $21.47 million.
Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $45.64 versus the stock’s reported $37.45 price.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the company's stock in a transaction that occurred on Tuesday, October 20th. The stock was sold at an average price of $35.11, for a total transaction of $7,022,000.00. Following the transaction, the chief executive officer owned 1,399,154 shares of the company's stock, valued at approximately $49,124,296.94. This represents a 12.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Trump Index: 6 Companies Linked to Trump’s Cabinet Worth Watching

Eric Venker also recently made the following trade(s):

On Wednesday, September 30th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $36.62, for a total transaction of $7,324,000.00.
On Friday, August 28th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $35.77, for a total transaction of $7,154,000.00.
On Monday, July 27th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $34.95, for a total transaction of $6,990,000.00.

Roivant Sciences Stock Performance

Shares of NASDAQ:ROIV opened at $37.45 on Friday. The company has a fifty day moving average of $36.61 and a 200-day moving average of $33.32. The company has a market capitalization of $27.05 billion, a PE ratio of -70.66 and a beta of 1.10. Roivant Sciences Ltd. has a 52-week low of $17.89 and a 52-week high of $42.50.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. The company had revenue of $1.44 million during the quarter, compared to analysts' expectations of $2.06 million. On average, equities analysts forecast that Roivant Sciences Ltd. will post -2.00 EPS for the current fiscal year.

Institutional Trading of Roivant Sciences

Several institutional investors have recently modified their holdings of ROIV. Alpine Bank Wealth Management acquired a new stake in Roivant Sciences in the third quarter valued at $25,000. Parallel Advisors LLC raised its position in Roivant Sciences by 33.7% during the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company's stock worth $57,000 after purchasing an additional 520 shares during the last quarter. Bessemer Group Inc. raised its position in Roivant Sciences by 21.8% during the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company's stock worth $69,000 after purchasing an additional 441 shares during the last quarter. Root Financial Partners LLC lifted its holdings in Roivant Sciences by 187.9% during the 1st quarter. Root Financial Partners LLC now owns 2,914 shares of the company's stock worth $81,000 after buying an additional 1,902 shares during the period. Finally, Acropolis Investment Management LLC acquired a new position in Roivant Sciences during the 3rd quarter worth about $134,000. Institutional investors own 64.76% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. TD Cowen reiterated a "buy" rating on shares of Roivant Sciences in a research report on Wednesday. Stifel Nicolaus assumed coverage on Roivant Sciences in a report on Wednesday, September 16th. They set a "buy" rating and a $51.00 price target on the stock. Sanford C. Bernstein raised Roivant Sciences to a "strong-buy" rating in a research note on Wednesday, July 29th. HC Wainwright raised their price objective on shares of Roivant Sciences from $41.00 to $47.00 and gave the company a "buy" rating in a report on Tuesday, September 8th. Finally, UBS Group set a $55.00 price objective on shares of Roivant Sciences in a report on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Roivant Sciences has a consensus rating of "Moderate Buy" and an average target price of $45.64.

Read Our Latest Stock Report on ROIV

Roivant Sciences News Roundup

Here are the key news stories impacting Roivant Sciences this week:

Positive Sentiment: Brepocitinib met both Phase 3 primary endpoints. Roivant and Priovant reported that the CLARITY-1 and CLARITY-2 trials achieved their primary goals in non-infectious uveitis. The drug also delivered statistically significant and clinically meaningful improvements in key secondary measures, including sustained steroid-free disease control, reduced vascular leakage, resolution of macular edema and better patient-reported visual functioning. Roivant and Priovant announce positive brepocitinib Phase 3 results
Positive Sentiment: The trial data could expand the drug’s commercial opportunity. Coverage highlighted brepocitinib’s ability to reduce reliance on steroids in inflammatory eye disease, while Roivant is expected to pursue a label expansion for Lisraya in uveitis. Positive commentary and analyst coverage contributed to the stock’s upward move. Roivant’s TYK2/JAK inhibitor reduces need for steroids
Neutral Sentiment: Roivant will report fiscal second-quarter results on November 9, 2026. Investors will receive updated financial results and a business outlook, including any regulatory or commercialization plans related to brepocitinib. Roivant quarterly earnings announcement
Negative Sentiment: CEO Eric Venker sold 200,000 shares worth approximately $7.0 million. The sale reduced his direct ownership by 12.5%, which may draw investor attention. However, it was executed under a pre-arranged Rule 10b5-1 trading plan, reducing its significance as a discretionary bearish signal. SEC insider transaction filing

About Roivant Sciences

(Get Free Report)

Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.

Roivant's research and development activities have included immunology, dermatology, women's health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.